Back to Search
Start Over
Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update
- Source :
- Expert Opinion on Biological Therapy. 20:1237-1244
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- Asthma exhibits marked heterogeneity in symptoms with severe or refractory asthma representing a clear area of unmet medical need. These patients require more specifically targeted treatments with monoclonal antibody-based biologics targeted at inhibition of the type 2 cytokines IL-4, IL-5 and IL-13 having considerable potential as effective treatments for severe asthma. For the most part, anti-cytokine-based biologic therapies are more likely to give significant clinical benefit in carefully selected patient populations that take asthma phenotypes and endotypes into account.This review is based on recent English-language original articles in Pub Med or MedLine that reported significant clinical findings on the current status, therapeutic potential and safety of the anti-IL-5 biologics mepolizumab, reslizumab and benralizumab in the treatment of severe refractory asthma.Anti-IL-5 treatment appears effective in patients with eosinophilic asthma through exacerbation prevention with accumulating evidence of glucocorticoid-sparing effects with an acceptable safety profile for these biologics.
- Subjects :
- 0301 basic medicine
medicine.drug_class
Clinical Biochemistry
Antibodies, Monoclonal, Humanized
Monoclonal antibody
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Reslizumab
immune system diseases
Drug Discovery
medicine
Humans
Anti-Asthmatic Agents
Glucocorticoids
Interleukin 5
Asthma
Pharmacology
business.industry
Antibodies, Monoclonal
Benralizumab
medicine.disease
respiratory tract diseases
Anti il 5
Treatment Outcome
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
Immunology
Marked heterogeneity
Immunotherapy
Interleukin-5
business
Mepolizumab
medicine.drug
Subjects
Details
- ISSN :
- 17447682 and 14712598
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Biological Therapy
- Accession number :
- edsair.doi.dedup.....4aa694f45a12400cb448f57090e9c78a